Michel Vautier

Discovery of (<i>R</i>)-8-(1-(3,5-Difluorophenylamino)ethyl)-<i>N</i>,<i>N</i>-dimethyl-2-morpholino-4-oxo-4<i>H</i>-chromene-6-carboxamide (AZD8186): A Potent and Selective Inhibitor of PI3Kβ and PI3Kδ for the Treatment of PTEN-Deficient Cancers

Bernard Barlaam, Sabina Cosulich, Sébastien L. Degorce et al. · Journal of Medicinal Chemistry · 2014 · 87 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +13

Discovery of 1-(4-(5-(5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1-ethyl-1,2,4-triazol-3-yl)piperidin-1-yl)-3-hydroxypropan-1-one (AZD8835): A potent and selective inhibitor of PI3Kα and PI3Kδ for the treatment of cancers

Bernard Barlaam, Sabina Cosulich, Bénédicte Delouvrié et al. · Bioorganic & Medicinal Chemistry Letters · 2015 · 35 citations

Medicine, Medicinal Chemistry, Pharmacology +8

New heterocyclic analogues of 4-(2-chloro-5-methoxyanilino)quinazolines as potent and selective c-Src kinase inhibitors

Bernard Barlaam, Mike Fennell, Hervé Germain et al. · Bioorganic & Medicinal Chemistry Letters · 2005 · 28 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +14

A new series of neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase

Bernard Barlaam, Peter Ballard, Robert H. Bradbury et al. · Bioorganic & Medicinal Chemistry Letters · 2007 · 18 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase

Bernard Barlaam, David Acton, Peter Ballard et al. · Bioorganic & Medicinal Chemistry Letters · 2008 · 10 citations

Medicine, Medicinal Chemistry, Pharmacology +14